Comparison of the anti-inflammatory effects of induced pluripotent stem cell–derived and bone marrow–derived mesenchymal stromal cells in a murine model of corneal injury

Cytotherapy

Volumn 19, Issue 1, 2017, Pages 28-35

  Yun, Young In ^a   Park, Se Yeon ^b   Lee, Hyun Ju ^b   Ko, Jung Hwa ^b   Kim, Mee Kum ^b   Wee, Won Ryang ^b   Reger, Roxanne L ^c   Gregory, Carl A ^c   Choi, Hosoon ^c   Fulcher, Samuel F ^d   Prockop, Darwin J ^c   Oh, Joo Youn ^b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bone marrow; cornea; induced pluripotent stem cell; inflammation; mesenchymal stromal cells

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; CELL ADHESION MOLECULE; IL1B PROTEIN, MOUSE; TNFAIP6 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA INJURY; CORNEA OPACITY; HISTOPATHOLOGY; INDUCED PLURIPOTENT STEM CELL; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DISEASE MODEL; GENETICS; KERATITIS; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY; TRANSPLANTATION;

ANIMALS; BONE MARROW CELLS; CELL ADHESION MOLECULES; CORNEAL INJURIES; CORNEAL OPACITY; DISEASE MODELS, ANIMAL; INDUCED PLURIPOTENT STEM CELLS; INTERLEUKIN-1BETA; INTERLEUKIN-6; KERATITIS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006314312     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.10.007     Document Type: Article

References (28)

1. [1] Prockop, D.J., Inflammation, fibrosis, and modulation of the process by mesenchymal stem/stromal cells. Matrix Biol 51 (2016), 7–13.
2. [2] Uccelli, A., Prockop, D.J., Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?. Curr Opin Immunol 22 (2010), 768–774.
3. [3] Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008), 1579–1586.
4. [4] English, K., Wood, K.J., Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med, 3, 2013, a015560.
5. [5] Reger, R.L., Prockop, D.J., Should publications on mesenchymal stem/progenitor cells include in-process data on the preparation of the cells?. Stem Cells Transl Med 3 (2014), 632–635.
6. [6] Phinney, D.G., Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle 6 (2007), 2884–2889.
7. [7] Ho, A.D., Wagner, W., Franke, W., Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 10 (2008), 320–330.
8. [8] Whitfield, M.J., Lee, W.C., Van Vliet, K.J., Onset of heterogeneity in culture-expanded bone marrow stromal cells. Stem Cell Res 11 (2013), 1365–1377.
9. [9] Larson, B.L., Ylostalo, J., Lee, R.H., Gregory, C., Prockop, D.J., Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue Eng Part A 16 (2010), 3385–3394.
10. [10] Tolar, J., Nauta, A.J., Osborn, M.J., Panoskaltsis Mortari, A., McElmurry, R.T., Bell, S., et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25 (2007), 371–379.
11. [11] Viswanathan, S., Keating, A., Deans, R., Hematti, P., Prockop, D., Stroncek, D.F., et al. Soliciting strategies for developing cell-based reference materials to advance MSC research and clinical translation. Stem Cells Dev 23 (2014), 1157–1167.
12. [12] Karnoub, A.E., Dash, A.B., Vo, A.P., Sullivan, A., Brooks, M.W., Bell, G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (2007), 557–563.
13. [13] Li, H.J., Reinhardt, F., Herschman, H.R., Weinberg, R.A., Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2 (2012), 840–855.
14. [14] Barkholt, L., Flory, E., Jekerle, V., Lucas-Samuel, S., Ahnert, P., Bisset, L., et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies—bridging scientific observations and regulatory viewpoints. Cytotherapy 15 (2013), 753–759.
15. [15] Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell 11 (2012), 812–824.
16. [16] Zhao, Q., Gregory, C.A., Lee, R.H., Reger, R.L., Qin, L., Hai, B., et al. MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proc Natl Acad Sci USA 112 (2015), 530–535.
17. [17] Roddy, G.W., Oh, J.Y., Lee, R.H., Bartosh, T.J., Ylostalo, J., Coble, K., et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6. Stem Cells 29 (2011), 1572–1579.
18. [18] Sekiya, I., Larson, B.L., Smith, J.R., Pochampally, R., Cui, J.G., Prockop, D.J., Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 20 (2002), 530–541.
19. [19] Lee, R.H., Pulin, A.A., Seo, M.J., Kota, D.J., Ylostalo, J., Larson, B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5 (2009), 54–63.
20. [20] Oh, J.Y., Roddy, G.W., Choi, H., Lee, R.H., Ylöstalo, J.H., Rosa, R.H. Jr, et al. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci USA 107 (2010), 16875–16880.
21. [21] Friedenstein, A.J., Chailakhjan, R.K., Lalykina, K.S., The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3 (1970), 393–403.
22. [22] Caplan, A.I., Mesenchymal stem cells. J Orthop Res 9 (1991), 641–650.
23. [23] Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999), 143–147.
24. [24] Kota, D.J., Wiggins, L.L., Yoon, N., Lee, R.H., TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Diabetes 62 (2013), 2048–2058.
25. [25] Oh, J.Y., Kim, M.K., Shin, M.S., Lee, H.J., Ko, J.H., Wee, W.R., et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 26 (2008), 1047–1055.
26. [26] Syed, B.A., Evans, J.B., Stem cell therapy market. Nat Rev Drug Discov 12 (2013), 185–186.
27. [27] Oh, J.Y., Choi, H., Lee, R.H., Roddy, G.W., Ylöstalo, J.H., Wawrousek, E., et al. Identification of the HSPB4/TLR2/NF-κB axis in macrophage as a therapeutic target for sterile inflammation of the cornea. EMBO Mol Med 4 (2012), 435–448.
28. [28] Bunker, D.J., George, R.J., Kleinschmidt, A., Kumar, R.J., Maitz, P., Alkali-related ocular burns: a case series and review. J Burn Care Res 35 (2014), 261–268.